Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-01 plus standard of care vs standard of care in acute-on-chronic liver failure with ascites
2021-002617-33Phase 2Active
- Sponsor
- Versantis AG
- Start
- Jul 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute-on-chronic liver failure (ACLF), Cirrhosis and ascites comparing VS-01 plus standard of care with Standard of care alone (2 arms). Primary endpoint: Change in CLIF-C ACLF score at Day 7. Started Jul 2021; status: active.
02
Drugs
VS-01-HAC
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosisascites
Beyond the preview
Go deeper on 2021-002617-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002617-33.